Hennion & Walsh Asset Management, Inc. Vir Biotechnology, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.06 Billion
- Q3 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 35,132 shares of VIR stock, worth $236,789. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,132
Previous 38,822
9.5%
Holding current value
$236,789
Previous $345,000
23.77%
% of portfolio
0.01%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding VIR
# of Institutions
219Shares Held
87.4MCall Options Held
127KPut Options Held
1.19M-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$112 Million1.03% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$111 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$88.5 Million0.0% of portfolio
-
State Street Corp Boston, MA5.63MShares$37.9 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.57MShares$24.1 Million0.63% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $894M
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...